Tizanidine Cubosomal Nano Carriers as Transdermal Delivery System: Preparation and Characterization
DOI:
https://doi.org/10.31351/vol35iss2pp50-65Abstract
Cubosomes are lipid-based nanostructured aqueous dispersions that form through a highly organized spontaneous self-assembly process. these lipid-based dosage forms can serve as effective carriers for lipophilic, hydrophilic drugs, thereby improving the therapeutic effectiveness of the drugs., cubosomes were developed in order to investigate their efficacy as nano carriers for transdermal delivery of tizanidine (TZN), a skeletal muscle relaxant with low oral bioavailability , cubosomal vesicles were formulated using the thin-film hydration technique, employing glyceryl monooleate (GMO) as the lipid component and poloxamer 407(p407) as the stabilizer. the vesicle characteristics were modified by varying the surfactant-to-lipid ratio. the prepared formulations were evaluated for vesicle size (VS), polydispersity index (PDI), and entrapment efficiency (%EE). the optimized formulation was further subjected to an in vitro release study, zeta potential measurement, field emission scanning electron microscopy (FESEM), and compatibility analysis using Fourier-transform infrared (FTIR) spectroscopy. additionally, differential scanning calorimetry (DSC) were conducted to compare the optimized formulation with the pure drug. the results demonstrated significant variations in certain physicochemical properties like particle size and EE. the optimized formulation, designated as F9, exhibited a vesicle size of 160.7 ± 4.785 nm, a PDI of 0.061 ± 0.048, an entrapment efficiency of 76.8 ± 0.17%, and a zeta potential of -23.46 ± 4.088mV, respectively, in vitro drug release study demonstrated controlled and sustain release profile from cubosomal dispersion photo micrographic analysis of the cubosomal dispersion confirmed a uniform cubic morphology with good dispersion stability. these findings suggest that the thin-film hydration technique is an effective approach for developing stable cubosomal dispersions
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Gupta L, Mittal A, Katrolia A, Raizaday A, Kaushik L, Shukla BK. Cubosomes: the pliant honeycombed nano-cargos in drug delivery applications. Nanomedicine J. 2024;11(2):1–18.
Bachhav AA, Pingale PL, Upasani CD, Ahire SA. Cubosome: a novel vesicular drug delivery system. Int J Pharm Sci Res. 2024;15(2):323–339.
Attri N, Shabbir M, Ali S, Hamid I, Sharif A, Akhtar MF, et al. Liposomes to cubosomes: the evolution of lipidic nanocarriers and their cutting-edge biomedical applications. ACS Appl Bio Mater. 2024;7(5):2677-2694. doi:10.1021/acsabm.4c00153.
Zhai J, Fong C, Tran N, Drummond CJ. Non-lamellar lyotropic liquid crystalline lipid nanoparticles for the next generation of nanomedicine. ACS Nano. 2019;13(6):6178–6206. doi:10.1021/acsnano.8b07961.
Sivadasan D, Sultan MH, Alqahtani SS, Javed S. Cubosomes in drug delivery—a comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines. 2023;11(4).
Garg G, Saraf S, Saraf S.Cubosomes: An Overview.Cubosomes: an overview.Biol Pharm Bull. 2007;30(2):350-353.
Chacko IA, Ghate VM, Dsouza L, Lewis SA. Lipid vesicles: a versatile drug delivery platform for dermal and transdermal applications. Colloids Surf B Biointerfaces. 2020;195:111262. doi:10. 1016/ j. colsurfb .2020.111262.
Urandur S, Marwaha D, Gautam S, Banala VT, Sharma M, Mishra PR. Nonlamellar liquid crystals: a new paradigm for the delivery of small molecules and bio-macromolecules. Ther Deliv. 2018;9(9):667-689.
Khedekar PB. Cubosomes: a vehicle for delivery of various therapeutic agents. MOJ Toxicol. 2018;4(1).
Li JC, Zhu N, Zhu JX, Zhang WJ, Zhang HM, Wang QQ, et al. Self-assembled cubic liquid crystalline nanoparticles for transdermal delivery of paeonol. Med Sci Monit. 2015;21:3298-3310.
Hasan MJ, Rajab NA. Nano vesicular topical drug delivery system: types, structural components, preparation techniques, and characterizations. J Emerg Med Trauma Acute Care. 2024;(6):16.
Zakaria F, Ashari SE, Mat Azmi ID, Abdul Rahman MB. Recent advances in encapsulation of drug delivery (active substance) in cubosomes for skin diseases. J Drug Deliv Sci Technol. 2022;68:103097. doi:10.1016/j.jddst.2022.103097.
Kaur SD, Singh G, Singh G, Singhal K, Kant S, Bedi N. Cubosomes as potential nanocarrier for drug delivery: a comprehensive review. J Pharm Res Int. 2021;33(31B):118–135. doi:10.9734/jpri/2021/v33i31b31698.
Chaudhary K, Sharma D. Cubosomes: a potential drug delivery system. Asian J Pharm Res Dev. 2021;9(5):93–101
Garg M, Goyal A, Kumari S. An update on the recent advances in cubosome: a novel drug delivery system. Curr Drug Metab. 2021;22(6):441–450.
Katekar VA, Deshmukh SP, Borkar RD, Rathod HK. Cubosome: an overview. J Surv Fish Sci. 2023;10(1):4397–4411.
Hartnett TE, O’Connor AJ, Ladewig K. Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics. Expert Opin Drug Deliv. 2015;12(9):1513–1526.
Peng X, Zhou Y, Han K, Qin L, Dian L, Li G, et al. Characterization of cubosomes as a targeted and sustained transdermal delivery system for capsaicin. Drug Des Devel Ther. 2015;9:4209–4218.
Mukherjee A, Chakravarty A. Spasticity mechanisms – for the clinician. Front Neurol. 2010 Mar;.
Wieters F, Weiss Lucas C, Gruhn M, Büschges A, Fink GR, Aswendt M. Introduction to spasticity and related mouse models. Exp Neurol. 2021;335:113491
Ghai A, Garg N, Hooda S, Gupta T. Spasticity - pathogenesis, prevention and treatment strategies. Saudi J Anaesth. 2013;7(4):453–460.
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140–175. doi:10. 1016 /j. jpain symman .2004.05.002.
Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435–452. doi:10.2165/00003495-199753030-00007.
Fadhel AY, Rajab NA. Tizanidine nano emulsion: formulation and in-vitro characterization. J Pharm Negative Results. 2022;13(3):572–581.
Peck J, Urits I, Crane J, McNally A, Noor N, Patel M, et al. Oral muscle relaxants for the treatment of chronic pain associated with cerebral palsy. Psychopharmacol Bull. 2020 Oct 15;50(4 Suppl 1):142–162. PMID: 33633423; PMCID: PMC7901132.
Arpa MD, Üstündağ Okur N, Gök MK, Cevher E. Chitosan-based buccal mucoadhesive bilayer tablets enhance the bioavailability of tizanidine hydrochloride by bypassing the first-pass metabolism. J Drug Deliv Sci Technol. 2024;105739.
Noor AH, Ghareeb MM. Formulation and evaluation of ondansetron HCl nanoparticles for transdermal delivery. Iraqi J Pharm Sci. 2020;29(2):70–79.
Shaik NB, Mortha SD, Lakshmi PK, Kukati L. Formulation and evaluation of tizanidine hydrochloride loaded ethosomes for transdermal delivery. J Pharm Sci Res. 2020;12(11):1400–1410
lbassam NY, Kassab HJ. Diacerein loaded novasome for transdermal delivery: preparation, in-vitro characterization and factors affecting formulation. Iraqi J Pharm Sci. 2023;32(Suppl):214–224.
Shabbir M, Sajid A, Hamid I, Sharif A, Akhtar MF, Raza M, et al. Influence of different formulation variables on the performance of transdermal drug delivery system containing tizanidine hydrochloride: in vitro and ex vivo evaluations. Braz J Pharm Sci. 2019;54:e00130.
Zaker H, Taymouri S, Mostafavi A. Formulation and physicochemical characterization of azithromycin-loaded cubosomes. Res Pharm Sci. 2023;18(1):49–58. doi:10.4103/1735-5362. 363 595.
Al-Tamimi DJ, Hussein AA. Formulation and characterization of self-microemulsifying drug delivery system of tacrolimus. Iraqi J Pharm Sci. 2021;30(1):91–100.
Ali SK, Al-Akkam EJ. Effects of different types of bile salts on the physical properties of ropinirole-loaded formulations. Al-Rafidain J Med Sci. 2023;5:134–142.
Mohsen AM, El-Hashemy HA, Salama A, Darwish AB. Formulation of tizanidine hydrochloride–loaded provesicular system for improved oral delivery and therapeutic activity employing a 2³ full factorial design. Drug Deliv Transl Res. 2023;13(2):580–592.
Alkufi HK, Kassab HJ. Soluplus-stabilized nimodipine-entrapped spanlastic formulations prepared with edge activator (Tween 20): comparative physicochemical evaluation. Pharm Nanotechnol. 2025;13(3):551–563. doi:10. 2174 / 0122117385348551241028102256.
Ghareeb MM. Formulation and characterization of isradipine as oral nanoemulsion. Iraqi J Pharm Sci. 2020;29(1):143–153.
Mansour M, Kamel AO, Mansour S, Mortada ND. Novel polyglycerol-dioleate based cubosomal dispersion with tailored physical characteristics for controlled delivery of ondansetron. Colloids Surf B Biointerfaces. 2017;156:44–54.
Ibraheem FQ, Al-Gawhri FJ. Preparation and in-vitro evaluation of baclofen as an oral microsponge tablet. Iraqi J Pharm Sci. 2019;28(1):75–90.
Fareed NY, Kassab HJ. Studying the effect of variables on acyclovir microsponge. Iraqi J Pharm Sci. 2018;66–76.
Kala S, Juyal D. Preformulation and characterization studies of aceclofenac active ingredient. Pharma Innov. 2016;5(9, Part B):110.
Abdulbaqi MR, Rajab NA. Preparation, characterization and ex vivo permeability study of transdermal apixaban O/W nanoemulsion-based gel. Iraqi J Pharm Sci. 2020;29(2):214–222.
Nashat BI, Al-Kinani KK. Nanoemulsion formulation of leflunomide for transdermal delivery: preparation and characterization. Int J Drug Deliv Technol. 2023;13(1):57–65.
Sabri L, Khalil M. Impact of formulation variables on meloxicam spanlastics preparation. Iraqi J Pharm Sci. 2024;33(4):59–68.
Alkawak RSY, Rajab NA. Lornoxicam-loaded cubosomes: preparation and in vitro characterization. Iraqi J Pharm Sci. 2022;31(1):144–153.
Amanat S, Taymouri S, Varshosaz J, Minaiyan M, Talebi A. Carboxymethyl cellulose-based wafer enriched with resveratrol-loaded nanoparticles for enhanced wound healing. Drug Deliv Transl Res. 2020;10:1241–1254.
Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1-2):137–144.
Elgindy NA, Mehanna MM, Mohyeldin SM. Self-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal delivery. Int J Pharm. 2016;501(1-2):167–179.
Eldeeb AE, Salah S, Ghorab M. Formulation and evaluation of cubosomes drug delivery system for treatment of glaucoma: ex-vivo permeation and in-vivo pharmacodynamic study. J Drug Deliv Sci Technol. 2019;52:236–247.
aymouri S, Varshosaz J, Hassanzadeh F, Haghjooy Javanmard S, Dana N. Optimization of processing variables effective on self-assembly of folate targeted Synpronic-based micelles for docetaxel delivery in melanoma cells. IET Nanobiotechnol. 2015;9(5):306–313.
Varshosaz J, Hassanzadeh F, Sadeghi-Aliabadi H, Firozian F. Uptake of etoposide in CT-26 cells of colorectal cancer using folate-targeted dextran stearate polymeric micelles. Biomed Res Int. 2014;2014:1–9.
Morsi NM, Mohamed MI, Refai H, El Sorogy HM. Nanoemulsion as a novel ophthalmic delivery system for acetazolamide. Int J Pharm Pharm Sci. 2014;6(11):227–236.
Teba HE, Khalil IA, El Sorogy HM. Novel cubosome-based system for ocular delivery of acetazolamide. Drug Deliv. 2021;28(1):2177–2186. doi:10.1080/10717544.2021.1989090.
The United States Pharmacopeia and National Formulary (USP 44, NF 39). Rockville, MD: United States Pharmacopeia Convention Inc; 2021.
Jagdale S, Brahmane S, Chabukswar A. Optimization of microemulgel for tizanidine hydrochloride. Anti-Inflamm Anti-Allergy Agents Med Chem. 2020;19(2):158–179.
Gupta R, Bajpai M. Influence of formulation parameters on tizanidine hydrochloride nanoparticles. Int J Pharm Bio Sci. 2013;4(2):1056–1078.
Pavithra K, Bhagawati ST, Manjunath K. Development and evaluation of tizanidine hydrochloride loaded solid lipid nanoparticles. Asian J Pharm Clin Res. 2019;12:152–158.
Németh Z, Csóka I, Semnani Jazani R, Sipos B, Haspel H, Kozma G, et al. Quality by design-driven zeta potential optimisation study of liposomes with charge imparting membrane additives. Pharmaceutics. 2022;14(9):1798. doi:10.3390/pharmaceutics14091798.
Badie H, Abbas H. Novel small self-assembled resveratrol-bearing cubosomes and hexosomes: preparation, characterization, and ex vivo permeation. Drug Dev Ind Pharm. 2018;44(12):2013–2025.
Ali Z, Sharma PK, Warsi MH. Fabrication and evaluation of ketorolac loaded cubosome for ocular drug delivery. J Appl Pharm Sci. 2016;6(9):204–208.
Boyd BJ, Whittaker DV, Khoo SM, Davey G. Hexosomes formed from glycerate surfactants formulation as a colloidal carrier for irinotecan. Int J Pharm. 2006;318(1-2):154–162.
Nath AG, Dubey P, Kumar A, Vaiphei KK, Rosenholm JM, Bansal KK, et al. Recent advances in the use of cubosomes as drug carriers with special emphasis on topical applications. J Lipids.2024;2024:2683466.
Mast MP, Modh H, Knoll J, Fecioru E, Wacker MG. An update to dialysis-based drug release testing data analysis and validation using the Pharma Test dispersion releaser. Pharmaceutics. 2021;13(12):2007. doi:10.3390/ pharmaceutics 13122007. PMID: 34959289.
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
